International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Temporal association of palliative care consultation with the trajectory of broad-spectrum antibiotic use at the end of life in advanced cancer: A nationwide linked cohort study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sim Jin-Ah, Yu Jiwon, Bae Jiyeon, Seo Jun-Won, Kim Jeong-Han, Yoo Shin Hye, Keam Bhumsuk
Аннотация
OBJECTIVES: We examined the temporal association between palliative care (PC) consultation and broad-spectrum antibiotic use near end-of-life trajectory.
METHODS: This retrospective cohort study used nationwide linked data to assess adults with advanced cancer (2018-2022) who died by June 2023. Broad-spectrum antibiotic use was evaluated using propensity score-matched analyses of prescription proportion (odds ratios [OR]) and days of therapy (DOT) per 1000 patient-days (relative risks [RR]) across predefined end-of-life intervals within the last six months of life.
RESULTS: Among 12,012 matched patients, 4102 received PC consultation. The PC group consistently showed lower prescription proportions than the non-PC group, from 6 to 3 months before death (58.3% vs 61.1%; OR, 0.89; 95% confidence interval [CI], 0.82-0.96) to the final week (13.8% vs 19.4%; OR, 0.66; 95% CI, 0.60-0.74). DOT differences emerged later, with significantly lower DOTs in the PC group during the final two weeks of life (113.7 vs 146.8; RR, 0.77; 95% CI, 0.61-0.99) and the final week (79.0 vs 116.0; RR, 0.68; 95% CI, 0.51-0.91).
CONCLUSION: PC consultation was associated with reduced broad-spectrum antibiotic use during end-of-life, suggesting that integrating PC into stewardship frameworks may mitigate antimicrobial selection pressure in patients with advanced cancer.
METHODS: This retrospective cohort study used nationwide linked data to assess adults with advanced cancer (2018-2022) who died by June 2023. Broad-spectrum antibiotic use was evaluated using propensity score-matched analyses of prescription proportion (odds ratios [OR]) and days of therapy (DOT) per 1000 patient-days (relative risks [RR]) across predefined end-of-life intervals within the last six months of life.
RESULTS: Among 12,012 matched patients, 4102 received PC consultation. The PC group consistently showed lower prescription proportions than the non-PC group, from 6 to 3 months before death (58.3% vs 61.1%; OR, 0.89; 95% confidence interval [CI], 0.82-0.96) to the final week (13.8% vs 19.4%; OR, 0.66; 95% CI, 0.60-0.74). DOT differences emerged later, with significantly lower DOTs in the PC group during the final two weeks of life (113.7 vs 146.8; RR, 0.77; 95% CI, 0.61-0.99) and the final week (79.0 vs 116.0; RR, 0.68; 95% CI, 0.51-0.91).
CONCLUSION: PC consultation was associated with reduced broad-spectrum antibiotic use during end-of-life, suggesting that integrating PC into stewardship frameworks may mitigate antimicrobial selection pressure in patients with advanced cancer.